IHE: Insite One passes interoperability tests

InSite One announced it successfully tested its Actor/Roles profiles at the recent 2010 Integrating the Healthcare Enterprise (IHE) Connectathon North America.

Connectathon North America, held in Chicago, serves as a weeklong industry-wide testing event where participants test their systems' ability to exchange information with complementary systems from multiple suppliers, performing all of the transactions required for the roles they have selected, called IHE Actors, in support of defined clinical use cases, called IHE Profiles.

This year, 104 companies participated with more than 150 health IT systems conducting 3,640 tests.

The Wallingford, Conn.-based InSite One said its data exchange testing included the Document Source/Document Consumer actors for the Cross-Enterprise Clinical Documents Share (XDS.b) profile as well as the Imaging Document Source/Imaging Document Consumer actors for the new Cross-Enterprise Document Sharing for Imaging (XDS-I.b) profile. The systems integration testing included more than 20 health IT suppliers. 

By incorporating these IHE elements into the InDex services, InSite One said it provides secure methods for sharing of information across the enterprise, into the EMR and beyond.

“Many of InSite One’s tests during this effort required standards-based integration of four disparate systems from four different organizations,”  said Robert Porper, InSite One's senior vice president of product development.

InSite One will participate in the HIMSS 2010 Interoperability Showcase in Atlanta, March 1 to 3.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.